Advertisement

Diagnosis and Surveillance of Barrett’s Esophagus

  • Oliver A. VarbanEmail author
Chapter

Abstract

Named after the Australian-born British thoracic surgeon Norman Barrett, Barrett’s esophagus refers to the abnormal replacement of normal stratified squamous epithelium of the distal esophagus with columnar-lined intestinal epithelium. Although the majority of patients do not have symptoms, gastroesophageal reflux is associated with an increased risk of Barrett’s esophagus. The diagnosis is made endoscopically by obtaining biopsies with confirmed intestinal metaplasia, which is defined by the presence of acid mucin-containing goblet cells. Barrett’s esophagus is associated with an increased risk of esophageal adenocarcinoma, and histopathology is necessary in identifying cytologic changes involved during carcinogenesis. Appropriate screening and surveillance for Barrett’s esophagus is important in preventing the progression of esophageal adenocarcinoma, which is a significant predictor for cancer survival.

Keywords

Barrett’s esophagus Endoscopy Gastroesophageal reflux Esophageal adenocarcinoma 

References

  1. 1.
    Barrett NR. Chronic peptic ulcer of the oesophagus and ‘oesophagitis’. Br J Surg. 1950;38:175–82.CrossRefGoogle Scholar
  2. 2.
    Lord RV. Norman Barrett, “doyen of esophageal surgery”. Ann Surg. 1999;229:428–39.CrossRefGoogle Scholar
  3. 3.
    Barrett NR. Hiatus hernia: a review of some controversial points. Br J Surg. 1954;42:231–43.CrossRefGoogle Scholar
  4. 4.
    Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119:1149–58.CrossRefGoogle Scholar
  5. 5.
    Graham D, Lipman G, Sehgal V, Lovat LB. Monitoring the premalignant potential of Barrett’s oesophagus’. Frontline Gastroenterol. 2016;7:316–22.CrossRefGoogle Scholar
  6. 6.
    Johansson J, Håkansson HO, Mellblom L, et al. Prevalence of precancerous and other metaplasia in the distal oesophagus and gastro-oesophageal junction. Scand J Gastroenterol. 2005;40:893–902.CrossRefGoogle Scholar
  7. 7.
    Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825–31.CrossRefGoogle Scholar
  8. 8.
    Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano-Monghidoro study. Gut. 2008;57:1354–9.CrossRefGoogle Scholar
  9. 9.
    Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett’s esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol. 1997;92:1293–7.PubMedGoogle Scholar
  10. 10.
    Andrici J, Tio M, Cox MR, Eslick GD. Hiatal hernia and the risk of Barrett’s esophagus. J Gastroenterol Hepatol. 2013;28:415–31.CrossRefGoogle Scholar
  11. 11.
    Cook MB, Wild CP, Forman D. A systematic review and meta-analysis of the sex ratio for Barrett’s esophagus, erosive reflux disease, and nonerosive reflux disease. Am J Epidemiol. 2005;162:1050–61.CrossRefGoogle Scholar
  12. 12.
    Abrams JA, Fields S, Lightdale CJ, Neugut AI. Racial and ethnic disparities in the prevalence of Barrett’s esophagus among patients who undergo upper endoscopy. Clin Gastroenterol Hepatol. 2008;6:30–4.CrossRefGoogle Scholar
  13. 13.
    Kubo A, Cook MB, Shaheen NJ, et al. Sex-specific associations between body mass index, waist circumference and the risk of Barrett’s oesophagus: a pooled analysis from the international BEACON consortium. Gut. 2013;62:1684–91.CrossRefGoogle Scholar
  14. 14.
    Thrift AP, Kramer JR, Alsarraj A, El-Serag HB. Fat mass by bioelectrical impedance analysis is not associated with increased risk of Barrett esophagus. J Clin Gastroenterol. 2014;48:218–23.CrossRefGoogle Scholar
  15. 15.
    Chak A, Lee T, Kinnard MF, et al. Familial aggregation of Barrett’s oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut. 2002;51:323–8.CrossRefGoogle Scholar
  16. 16.
    Anderson LA, Cantwell MM, Watson RG, et al. The association between alcohol and reflux esophagitis, Barrett’s esophagus, and esophageal adenocarcinoma. Gastroenterology. 2009;136:799–805.CrossRefGoogle Scholar
  17. 17.
    Andrici J, Cox MR, Eslick GD. Cigarette smoking and the risk of Barrett’s esophagus: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2013;28:1258–73.CrossRefGoogle Scholar
  18. 18.
    Shaheen NJ, Falk GW, Iyer PG, Gerson LB, American COG. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50; quiz 51CrossRefGoogle Scholar
  19. 19.
    Singh S, Singh AG, Singh PP, Murad MH, Iyer PG. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:620–9.CrossRefGoogle Scholar
  20. 20.
    Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis. Gut. 2014;63:1229–37.CrossRefGoogle Scholar
  21. 21.
    Zhang S, Zhang XQ, Ding XW, et al. Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett’s esophagus: a meta-analysis. Br J Cancer. 2014;110:2378–88.CrossRefGoogle Scholar
  22. 22.
    Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology. 2006;131:1392–9.CrossRefGoogle Scholar
  23. 23.
    Peery AF, Hoppo T, Garman KS, et al. Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video). Gastrointest Endosc. 2012;75:945–953.e2.CrossRefGoogle Scholar
  24. 24.
    Shariff MK, Bird-Lieberman EL, O’Donovan M, et al. Randomized crossover study comparing efficacy of transnasal endoscopy with that of standard endoscopy to detect Barrett’s esophagus. Gastrointest Endosc. 2012;75:954–61.CrossRefGoogle Scholar
  25. 25.
    Sharma P, Hawes RH, Bansal A, et al. Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett’s oesophagus: a prospective, international, randomised controlled trial. Gut. 2013;62:15–21.CrossRefGoogle Scholar
  26. 26.
    Qumseya BJ, Wang H, Badie N, et al. Advanced imaging technologies increase detection of dysplasia and neoplasia in patients with Barrett’s esophagus: a meta-analysis and systematic review. Clin Gastroenterol Hepatol. 2013;11:1562–70.e1.CrossRefGoogle Scholar
  27. 27.
    Booth CL, Thompson KS. Barrett’s esophagus: a review of diagnostic criteria, clinical surveillance practices and new developments. J Gastrointest Oncol. 2012;3:232–42.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology. 1996;110:614–21.CrossRefGoogle Scholar
  29. 29.
    Goldblum JR. The significance and etiology of intestinal metaplasia of the esophagogastric junction. Ann Diagn Pathol. 2002;6:67–73.CrossRefGoogle Scholar
  30. 30.
    Zhu W, Appelman HD, Greenson JK, et al. A histologically defined subset of high-grade dysplasia in Barrett mucosa is predictive of associated carcinoma. Am J Clin Pathol. 2009;132:94–100.CrossRefGoogle Scholar
  31. 31.
    Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32:368–78.CrossRefGoogle Scholar
  32. 32.
    Shi XY, Bhagwandeen B, Leong AS. p16, cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus. Appl Immunohistochem Mol Morphol. 2008;16:447–52.CrossRefGoogle Scholar
  33. 33.
    van Dekken H, Hop WC, Tilanus HW, et al. Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus. Am J Clin Pathol. 2008;130:745–53.CrossRefGoogle Scholar
  34. 34.
    Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett’s esophagus III: baseline flow cytometric variables. Am J Gastroenterol. 2001;96:3071–83.CrossRefGoogle Scholar
  35. 35.
    Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett’s esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol. 2000;95:1669–76.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Schulmann K, Sterian A, Berki A, et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett’s-associated neoplastic progression and predicts progression risk. Oncogene. 2005;24:4138–48.CrossRefGoogle Scholar
  37. 37.
    Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8:235–44; quiz e32CrossRefGoogle Scholar
  38. 38.
    Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277–88.CrossRefGoogle Scholar
  39. 39.
    Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett’s esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc. 2005;62:488–98.CrossRefGoogle Scholar
  40. 40.
    Bamehriz F, Dutta S, Pottruff CG, Allen CJ, Anvari M. Does laparoscopic Nissen fundoplication prevent the progression of Barrett’s oesophagus? Is the length of Barrett’s a factor. J Minim Access Surg. 2005;1:21–8.CrossRefGoogle Scholar
  41. 41.
    Hofstetter WL, Peters JH, DeMeester TR, et al. Long-term outcome of antireflux surgery in patients with Barrett’s esophagus. Ann Surg. 2001;234:532–8; discussion 538CrossRefGoogle Scholar
  42. 42.
    Ganz RA, Edmundowicz SA, Taiganides PA, et al. Long-term outcomes of patients receiving a magnetic sphincter augmentation device for gastroesophageal reflux. Clin Gastroenterol Hepatol. 2016;14:671–7.CrossRefGoogle Scholar

Copyright information

© SAGES 2019

Authors and Affiliations

  1. 1.Department of General Surgery, Michigan MedicineUniversity Hospital, University of MichiganAnn ArborUSA

Personalised recommendations